Researcher
Tim Lammens
- Keywords:acute myeloid leukemi, inherited predisposition for cancer, asparaginase, neuroblastoma, juvenile myelomonocytic leukemia, pediatric oncology
- Disciplines:Molecular and cell biology not elsewhere classified, Oncology not elsewhere classified, Genomics, Paediatrics
Affiliations
- Department of Internal Medicine and Pediatrics (Department)
Member
From1 Oct 2018 → Today - Department of Pediatrics and medical genetics (Department)
Member
From1 Jun 2009 → 30 Sep 2018 - Department of Plant Biotechnology and Bioinformatics (Department)
Member
From1 Oct 2004 → 31 Jan 2009
Projects
1 - 10 of 16
- Evaluating the predictive power of a set of adrenergic and mesenchymal coding - and - noncoding RNAs in neuroblastoma.From1 Mar 2024 → TodayFunding: Foreign foundations, funds with scientific view
- Facility : Patiënt-afgeleide xenograft modellen – UGent;From1 Feb 2024 → TodayFunding: BOF - research organisations
- Establishing safety and efficacy of an improved Asparaginase in dog models: final preparation for Phase I clinical trialFrom1 Jan 2024 → TodayFunding: Nonprofit institution or equivalents
- A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive AnalysisFrom1 Jan 2024 → TodayFunding: HORIZON.2.1 - Health
- Towards clinical testing of novel stabilized less toxic asparaginases for the treatment of acute lymphoblastic leukemiaFrom20 Dec 2023 → TodayFunding: IOF - technology validation in lab
- Research assignment of Prof. dr. Tim Lammens, framing the ongoing clinical-translational research at the Department of Pediatric Hematology-Oncology and Stem Cell TransplantationFrom1 Oct 2023 → TodayFunding: Nonprofit institution or equivalents
- Preclinical validation of a less toxic variant for paediatric leukemiaFrom1 Oct 2022 → 30 Sep 2023Funding: Nonprofit institution or equivalents
- A patient derived xenograft (PDX) platform for in vivo evaluation of novel anticancer therapiesFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- The impact of magnetic particulate matter (mPM) pollution as a contributing factor for development of childhood cancer: an in vitro and in vivo molecular and cellular analysis.From1 Nov 2021 → 31 Oct 2022Funding: Nonprofit institution or equivalents
- The use of a less toxic alternative asparaginase variant to treat metastatic breast cancerFrom1 Oct 2021 → TodayFunding: BOF - projects
Publications
1 - 10 of 36
- Drug response profiling informs personalized bridging to cell therapy for patients with relapsed/refractory acute lymphoblastic leukemia(2023)
Authors: Fabio D. Steffen, Andrej Lissat, Julia Alten, Cornelia Eckert, Bodmer Nicole, Thorhauge Als-Nielsen Bodil E., Adriana Balduzzi, Sarah Elitzur, Andras Kriston, Gergely Nyiri, et al.
Number of pages: 1 - In vivo stabilization of a less toxic asparaginase variant leads to a durable antitumor response in acute leukemia(2023)
Authors: Maaike Van Trimpont, Amanda M. Schalk, Yanti De Visser, Hien Anh Nguyen, Lindy Reunes, Katrien Vandemeulebroecke, Evelien Peeters, Ying Su, Hyun Lee, Philip L. Lorenzi, et al.
Pages: 409 - 419 - Mutational permutations of a single amino acid exert divergent phenotypic effects in human, mice and cellular models of SAMD9L bone marrow failure disorder(2022)Volume: 140
Authors: Sushree S Sahoo, Charnise Goodings-Harris, Shondra Miller, Maria Angeles Lillo Osuna, Baranda S Hansen, Lei Han, Ti-Cheng Chang, Tim Lammens, Mattias Hofmans, Marta Derecka, et al.
Pages: 2216 - 2217 - A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues(2022)
Authors: Tom Luijts, Kerryn Elliott, Joachim Siaw, Joris Van de Velde, Elien Beyls, Arne Claeys, Tim Lammens, Erik Larsson, Wouter Willaert, Anne Vral, et al.
- Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma : a BEACON-Neuroblastoma biomarker study(2022)Volume: 40
Authors: Lucas Moreno, Rebekah Weston, Virginie Viprey, Andrei Tchirkov, Maria Corrias, Tim Lammens, Juliet Gray, Cormac Owens, Jennifer Laidler, Marion Gambart, et al.
Number of pages: 1 - Targeted therapy in juvenile myelomonocytic leukemia : where are we now?(2022)
Authors: Nele De Vos, Mattias Hofmans, Tim Lammens, Bram De Wilde, Nadine Van Roy, Barbara De Moerloose
- Correction to : functional classification of RUNX1 variants in familial platelet disorder with associated myeloid malignancies(2022)
Authors: Melanie Decker, Tim Lammens, Alina Ferster, Miriam Erlacher, Ayami Yoshimi, Charlotte M. Niemeyer, Martijn P. T. Ernst, Marc H. G. P. Raaijmakers, Nicolas Duployez, Andreas Flaum, et al.
Pages: 2949 - 2949 - Novel insights on the use of L-asparaginase as an efficient and safe anti-cancer therapy(2022)
Authors: Maaike Van Trimpont, Evelien Peeters, Yanti De Visser, Amanda M. Schalk, Veerle Mondelaers, Barbara De Moerloose, Arnon Lavie, Tim Lammens, Steven Goossens, Pieter Van Vlierberghe
- Evaluation of PEG-L-asparaginase in asparagine suppression and anti-drug antibody development in healthy Beagle dogs : a multi-phase preclinical study(2022)
Authors: L.R. Feenstra, R. Gehring, I.M. van Geijswijk, T. König, H.C.M.T Prinsen, Katrien Vandemeulebroecke, Tim Lammens, A. Krupa, E. Teske
- Tracking the molecular fingerprint of head and neck cancer for recurrence detection in liquid biopsies(2022)
Authors: Araceli Diez-Fraile, Joke De Ceulaer, Charlotte Derpoorter, Christophe Spaas, Tom De Backer, Philippe Lamoral, Johan Abeloos, Tim Lammens